Your browser doesn't support javascript.
loading
Are high-risk prostate cancer patients being treated equally? The impact of PSA.
Kord, Eyal; Ferenczi, Basil; DiNatale, Renzo G; Daily, Adam; Koenig, Hannah; Frankel, Jason; Jung, Nathan; Flores, John Paul; Porter, Christopher.
Afiliação
  • Kord E; Virginia Mason Franciscan Health, Section of Urology, Seattle WA.
  • Ferenczi B; Virginia Mason Franciscan Health, Section of Urology, Seattle WA.
  • DiNatale RG; Virginia Mason Franciscan Health, Section of Urology, Seattle WA.
  • Daily A; Virginia Mason Franciscan Health, Section of Urology, Seattle WA.
  • Koenig H; Virginia Mason Franciscan Health, Section of Urology, Seattle WA.
  • Frankel J; Virginia Mason Franciscan Health, Section of Urology, Seattle WA.
  • Jung N; Virginia Mason Franciscan Health, Section of Urology, Seattle WA.
  • Flores JP; Virginia Mason Franciscan Health, Section of Urology, Seattle WA.
  • Porter C; Virginia Mason Franciscan Health, Section of Urology, Seattle WA. Electronic address: Christopher.porter@commonspirit.org.
Urol Oncol ; 41(4): 204.e17-204.e25, 2023 04.
Article em En | MEDLINE | ID: mdl-36918337
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Antígeno Prostático Específico Idioma: En Ano de publicação: 2023 Tipo de documento: Article